Mylan Inc. (MYL) is a pharmaceutical company that develops, manufactures, and markets generic, branded generic, and specialty pharmaceuticals. The company's products are used to treat a wide range of medical conditions, including infectious diseases, cardiovascular disease, respiratory illness, and cancer.
Mylan has a diverse portfolio of products, with a focus on developing and commercializing complex generics and biosimilars. Some of its key products include EpiPen, a lifesaving emergency treatment for severe allergic reactions, and HIV/AIDS drugs such as Atripla and Truvada.
In addition to its pharmaceutical business, Mylan has a global presence in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates in more than 165 countries and has a workforce of approximately 35,000 employees.
Mylan has a strong commitment to quality and safety, with a focus on improving patient access to affordable healthcare. The company has been recognized for its efforts in providing access to high-quality, affordable medicines, and has been named to Fortune magazine's "World's Most Admired Companies" list for several years.
Mylan is headquartered in Canonsburg, Pennsylvania, and is publicly traded on the NASDAQ stock exchange under the ticker symbol MYL.
|
